Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report
Baricitinib is a Janus kinase 1/2 (JAK1/2) inhibitor used in the treatment of rheumatoid arthritis. A 71-year-old woman with rheumatoid arthritis complicated by systemic sclerosis and type 1 diabetes that were resistant to multiple disease-modifying antirheumatic drugs started treatment with baricit...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Rheumatology |
| Online Access: | http://dx.doi.org/10.1155/2019/5293981 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554162647203840 |
|---|---|
| author | Yuya Fujita Masao Nawata Atsushi Nagayasu Kazuki Someya Kazuyoshi Saito Yoshiya Tanaka |
| author_facet | Yuya Fujita Masao Nawata Atsushi Nagayasu Kazuki Someya Kazuyoshi Saito Yoshiya Tanaka |
| author_sort | Yuya Fujita |
| collection | DOAJ |
| description | Baricitinib is a Janus kinase 1/2 (JAK1/2) inhibitor used in the treatment of rheumatoid arthritis. A 71-year-old woman with rheumatoid arthritis complicated by systemic sclerosis and type 1 diabetes that were resistant to multiple disease-modifying antirheumatic drugs started treatment with baricitinib. After baricitinib administration, the disease activity of her rheumatoid arthritis was attenuated from the early stage of treatment, and the effect was maintained for up to 52 weeks. In addition, the skin sclerosis in systemic sclerosis showed an improvement. Regarding the influence on type 1 diabetes, the required daily dose of insulin and hemoglobin A1c (HbA1c) levels decreased. To date, no studies have demonstrated the effectiveness of baricitinib on systemic sclerosis or type 1 diabetes. We report that baricitinib was effective for systemic sclerosis and type 1 diabetes, as well as for rheumatoid arthritis, for up to 52 weeks. |
| format | Article |
| id | doaj-art-87733368391a4f2186b19b8164b911de |
| institution | Kabale University |
| issn | 2090-6889 2090-6897 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Rheumatology |
| spelling | doaj-art-87733368391a4f2186b19b8164b911de2025-02-03T05:52:13ZengWileyCase Reports in Rheumatology2090-68892090-68972019-01-01201910.1155/2019/52939815293981Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case ReportYuya Fujita0Masao Nawata1Atsushi Nagayasu2Kazuki Someya3Kazuyoshi Saito4Yoshiya Tanaka5The Department of Rheumatology, Tobata General Hospital, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JapanThe Department of Rheumatology, Tobata General Hospital, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JapanThe First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JapanThe Department of Rheumatology, Tobata General Hospital, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JapanThe Department of Rheumatology, Tobata General Hospital, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JapanThe First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JapanBaricitinib is a Janus kinase 1/2 (JAK1/2) inhibitor used in the treatment of rheumatoid arthritis. A 71-year-old woman with rheumatoid arthritis complicated by systemic sclerosis and type 1 diabetes that were resistant to multiple disease-modifying antirheumatic drugs started treatment with baricitinib. After baricitinib administration, the disease activity of her rheumatoid arthritis was attenuated from the early stage of treatment, and the effect was maintained for up to 52 weeks. In addition, the skin sclerosis in systemic sclerosis showed an improvement. Regarding the influence on type 1 diabetes, the required daily dose of insulin and hemoglobin A1c (HbA1c) levels decreased. To date, no studies have demonstrated the effectiveness of baricitinib on systemic sclerosis or type 1 diabetes. We report that baricitinib was effective for systemic sclerosis and type 1 diabetes, as well as for rheumatoid arthritis, for up to 52 weeks.http://dx.doi.org/10.1155/2019/5293981 |
| spellingShingle | Yuya Fujita Masao Nawata Atsushi Nagayasu Kazuki Someya Kazuyoshi Saito Yoshiya Tanaka Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report Case Reports in Rheumatology |
| title | Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report |
| title_full | Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report |
| title_fullStr | Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report |
| title_full_unstemmed | Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report |
| title_short | Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report |
| title_sort | fifty two week results of clinical and imaging assessments of a patient with rheumatoid arthritis complicated by systemic sclerosis with interstitial pneumonia and type 1 diabetes despite multiple disease modifying antirheumatic drug therapy that was successfully treated with baricitinib a novel case report |
| url | http://dx.doi.org/10.1155/2019/5293981 |
| work_keys_str_mv | AT yuyafujita fiftytwoweekresultsofclinicalandimagingassessmentsofapatientwithrheumatoidarthritiscomplicatedbysystemicsclerosiswithinterstitialpneumoniaandtype1diabetesdespitemultiplediseasemodifyingantirheumaticdrugtherapythatwassuccessfullytreatedwithbaricitinibanove AT masaonawata fiftytwoweekresultsofclinicalandimagingassessmentsofapatientwithrheumatoidarthritiscomplicatedbysystemicsclerosiswithinterstitialpneumoniaandtype1diabetesdespitemultiplediseasemodifyingantirheumaticdrugtherapythatwassuccessfullytreatedwithbaricitinibanove AT atsushinagayasu fiftytwoweekresultsofclinicalandimagingassessmentsofapatientwithrheumatoidarthritiscomplicatedbysystemicsclerosiswithinterstitialpneumoniaandtype1diabetesdespitemultiplediseasemodifyingantirheumaticdrugtherapythatwassuccessfullytreatedwithbaricitinibanove AT kazukisomeya fiftytwoweekresultsofclinicalandimagingassessmentsofapatientwithrheumatoidarthritiscomplicatedbysystemicsclerosiswithinterstitialpneumoniaandtype1diabetesdespitemultiplediseasemodifyingantirheumaticdrugtherapythatwassuccessfullytreatedwithbaricitinibanove AT kazuyoshisaito fiftytwoweekresultsofclinicalandimagingassessmentsofapatientwithrheumatoidarthritiscomplicatedbysystemicsclerosiswithinterstitialpneumoniaandtype1diabetesdespitemultiplediseasemodifyingantirheumaticdrugtherapythatwassuccessfullytreatedwithbaricitinibanove AT yoshiyatanaka fiftytwoweekresultsofclinicalandimagingassessmentsofapatientwithrheumatoidarthritiscomplicatedbysystemicsclerosiswithinterstitialpneumoniaandtype1diabetesdespitemultiplediseasemodifyingantirheumaticdrugtherapythatwassuccessfullytreatedwithbaricitinibanove |